age 18 Years to 39 Years
Item
age 18 Years to 39 Years
boolean
C0001779 (UMLS CUI 2011AA)
397669002 (SNOMED CT 2011_0131)
Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment
Item
Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment
boolean
C0455628 (UMLS CUI 2011AA)
161649006 (SNOMED CT 2011_0131)
C1518321 (UMLS CUI 2011AA)
C0011854 (UMLS CUI 2011AA)
46635009 (SNOMED CT 2011_0131)
10067584 (MedDRA 14.1)
MTHU020217 (LOINC Version 232)
E10 (ICD-10-CM Version 2010)
C0011900 (UMLS CUI 2011AA)
439401001 (SNOMED CT 2011_0131)
MTHU008876 (LOINC Version 232)
C1704788 (UMLS CUI 2011AA)
C1705019 (UMLS CUI 2011AA)
CL414621 (UMLS CUI 2011AA)
Male patient or female patient using adequate contraceptive methods
Item
Male patient or female patient using adequate contraceptive methods
boolean
C0086582 (UMLS CUI 2011AA)
248153007 (SNOMED CT 2011_0131)
M (HL7 V3 2006_05)
C0086287 (UMLS CUI 2011AA)
248152002 (SNOMED CT 2011_0131)
F (HL7 V3 2006_05)
C0205411 (UMLS CUI 2011AA)
88323005 (SNOMED CT 2011_0131)
C0700589 (UMLS CUI 2011AA)
146680009 (SNOMED CT 2011_0131)
10010808 (MedDRA 14.1)
Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA
Item
Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA
boolean
C1335447 (UMLS CUI 2011AA)
C0011849 (UMLS CUI 2011AA)
191044006 (SNOMED CT 2011_0131)
C0699792 (UMLS CUI 2011AA)
263498003 (SNOMED CT 2011_0131)
C0004358 (UMLS CUI 2011AA)
30621004 (SNOMED CT 2011_0131)
MTHU031562 (LOINC Version 232)
C1414926 (UMLS CUI 2011AA)
C1419119 (UMLS CUI 2011AA)
C0201519 (UMLS CUI 2011AA)
64135003 (SNOMED CT 2011_0131)
10050516 (MedDRA 14.1)
History of a malignancy
Item
History of neoplastic disease
boolean
C0006826 (UMLS CUI 2011AA)
Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated > ten percent above the upper limit of normal, elevation of AST or ALT > 3 times the upper limit of normal
Item
Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated > ten percent above the upper limit of normal, elevation of AST or ALT > 3 times the upper limit of normal
boolean
C0023895 (UMLS CUI 2011AA)
235856003 (SNOMED CT 2011_0131)
10024670 (MedDRA 14.1)
K76.9 (ICD-10-CM Version 2010)
573.9 (ICD-9-CM Version 2011)
C0022658 (UMLS CUI 2011AA)
90708001 (SNOMED CT 2011_0131)
10029151 (MedDRA 14.1)
N18.9 (ICD-10-CM Version 2010)
CL414623 (UMLS CUI 2011AA)
C0201976 (UMLS CUI 2011AA)
113075003 (SNOMED CT 2011_0131)
10040230 (MedDRA 14.1)
C0004002 (UMLS CUI 2011AA)
26091008 (SNOMED CT 2011_0131)
MTHU004883 (LOINC Version 232)
C0001899 (UMLS CUI 2011AA)
56935002 (SNOMED CT 2011_0131)
MTHU006766 (LOINC Version 232)
C1519815 (UMLS CUI 2011AA)
Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator
Item
Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator
boolean
C0348080 (UMLS CUI 2011AA)
260905004 (SNOMED CT 2011_0131)
COND (HL7 V3 2006_05)
C0392760 (UMLS CUI 2011AA)
247591002 (SNOMED CT 2011_0131)
C0521982 (UMLS CUI 2011AA)
182985004 (SNOMED CT 2011_0131)
C0332281 (UMLS CUI 2011AA)
47429007 (SNOMED CT 2011_0131)
C0205217 (UMLS CUI 2011AA)
U (HL7 V3 2006_05)
C0679823 (UMLS CUI 2011AA)
PART (HL7 V3 2006_05)
C0035647 (UMLS CUI 2011AA)
30207005 (SNOMED CT 2011_0131)
RSK (HL7 V3 2006_05)
Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin
Item
Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin
boolean
C1524063 (UMLS CUI 2011AA)
260676000 (SNOMED CT 2011_0131)
C0003211 (UMLS CUI 2011AA)
16403005, 372665008 (SNOMED CT 2011_0131)
C0005525 (UMLS CUI 2011AA)
C0003364 (UMLS CUI 2011AA)
372586001 (SNOMED CT 2011_0131)
C0086440 (UMLS CUI 2011AA)
57952007 (SNOMED CT 2011_0131)
C0935929 (UMLS CUI 2011AA)
373245004 (SNOMED CT 2011_0131)
CL411789 (UMLS CUI 2011AA)
C0021641 (UMLS CUI 2011AA)
67866001 (SNOMED CT 2011_0131)
MTHU019392 (LOINC Version 232)
Pregnant or nursing women or women intending to become pregnant
Item
Pregnant or nursing women or women intending to become pregnant
boolean
C0043210 (UMLS CUI 2011AA)
224526002 (SNOMED CT 2011_0131)
C0549206 (UMLS CUI 2011AA)
10036586 (MedDRA 14.1)
C0006147 (UMLS CUI 2011AA)
10006247 (MedDRA 14.1)
C0032992 (UMLS CUI 2011AA)
169565003 (SNOMED CT 2011_0131)
Known or suspected allergy to atorvastatin or any component of the trial product
Item
Known or suspected allergy to atorvastatin or any component of the trial product
boolean
C0020517 (UMLS CUI 2011AA)
257550005 (SNOMED CT 2011_0131)
T78.40 (ICD-10-CM Version 2010)
C0286651 (UMLS CUI 2011AA)
373444002 (SNOMED CT 2011_0131)
C1705248 (UMLS CUI 2011AA)
C0304229 (UMLS CUI 2011AA)
902003 (SNOMED CT 2011_0131)
Known myopathy, myalgia or myositis with a serum-CPK > 3 times the upper limit of normal
Item
Known myopathy, myalgia or myositis with a serum-CPK > 3 times the upper limit of normal
boolean
C0026848 (UMLS CUI 2011AA)
129565002 (SNOMED CT 2011_0131)
10028641 (MedDRA 14.1)
G72.9 (ICD-10-CM Version 2010)
359.9 (ICD-9-CM Version 2011)
C0231528 (UMLS CUI 2011AA)
68962001 (SNOMED CT 2011_0131)
10028323 (MedDRA 14.1)
MTHU013523 (LOINC Version 232)
M79.1 (ICD-10-CM Version 2010)
E12485 (CTCAE 1105E)
C0027121 (UMLS CUI 2011AA)
26889001 (SNOMED CT 2011_0131)
10028653 (MedDRA 14.1)
M60.9 (ICD-10-CM Version 2010)
E12489 (CTCAE 1105E)
C0750860 (UMLS CUI 2011AA)
10040222 (MedDRA 14.1)
C1519815 (UMLS CUI 2011AA)
Patients who had a severe blood loss (>= 400 mL, e.g. blood donation) within 2 months prior to visit 2
Item
Patients who had a severe blood loss (>= 400 mL, e.g. blood donation) within 2 months prior to visit 2
boolean
C0205082 (UMLS CUI 2011AA)
24484000 (SNOMED CT 2011_0131)
CL353706 (UMLS CUI 2011AA)
C0005794 (UMLS CUI 2011AA)
25179006 (SNOMED CT 2011_0131)
Any significant laboratory abnormality
Item
Any significant laboratory abnormality
boolean
C0750502 (UMLS CUI 2011AA)
386134007 (SNOMED CT 2011_0131)
C0438215 (UMLS CUI 2011AA)
165346000 (SNOMED CT 2011_0131)
10023547 (MedDRA 14.1)
A serum LDL-cholesterol > 150 mg/dL at time of screening
Item
A serum LDL-cholesterol > 150 mg/dL at time of screening
boolean
C0428474 (UMLS CUI 2011AA)
166833005 (SNOMED CT 2011_0131)
C0439547 (UMLS CUI 2011AA)
272105005 (SNOMED CT 2011_0131)
C1409616 (UMLS CUI 2011AA)
Unwillingness to comply with study procedures
Item
Unwillingness to comply with study procedures
boolean
C0558080 (UMLS CUI 2011AA)
225465005 (SNOMED CT 2011_0131)
C1321605 (UMLS CUI 2011AA)
405078008 (SNOMED CT 2011_0131)
C0680734 (UMLS CUI 2011AA)